Tyverb

This page shows the latest Tyverb news and features for those working in and with pharma, biotech and healthcare.

Pfizer’s first-in-class breast cancer therapy wins EU licence

A number of metastatic breast cancer treatments have been rejected by the UK cost-effectiveness watchdog over the last few years, including GlaxoSmithKline's Tyverb (lapatinib) and Roche's Herceptin (trastuzumab),

Latest news

Oncology directions

For advanced breast cancer, Novartis's newly acquired breast cancer drug Tyverb (lapatinib) scores five, but there are four drugs that score three or less, including Eisai's breast cancer medicine
Novartis and GSK complete oncology and vaccines swap

Details of the asset swap were first revealed last April. Novartis claims ownership of several marketed products - including kidney cancer therapy Votrient (pazopanib) and Tyverb (lapatinib) for breast cancer - and also
England's Cancer Drugs Fund: Fixing a broken system

eribulin), GSK's Tyverb (lapatinib) and Novartis' Afinitor (everolimus)), were to be de-listed. ... GlaxoSmithKline's Tyverb (lapatinib):. treatment of advanced breast cancer. GlaxoSmithKline's Arzerra (ofatumumab):.
Pharma condemns Cancer Drugs Fund cuts

GSK. Arzerra (ofatumumab). Chronic lymphocytic leukaemia. Tyverb (lapatinib). Breast cancer. Votrient (pazopanib).
NHS names drugs to be re-evaluated for Cancer Drugs Fund

Chronic lymphocytic leukaemia. GlaxoSmithKline. Arzerra (ofatumumab) . Chronic lymphocytic leukaemia. Tyverb (lapatinib).

More from news
Approximately 3 fully matching, plus 26 partially matching documents found.

Latest appointments

GSK's oncology president joins NuCana board

During this time he has worked on major cancer products, such as Tykerb/Tyverb and Mekinist.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Medical (Scientific) Director: £120, 000 benefits

Associate Director: £75, 000-90, 000

Account Manager / Senior Account Manager: 35, 000-40, 000

Business Development Director – Health Education: excellent commission

SAE – Healthcare PR – Award-Winning Consultancy: Salary TBC

Account Executive/ Senior Account Executive: competitive Salary Offfered

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Systematic Reviewer - Oxford: Negotiable

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Account Manager: Negotiable

Experienced Medical Writers: Competitive Salary and Benefits

Business Director: Competitive Salary Offered

CALLING ALL SENIOR HEALTHCARE PR FREELANCERS!!!!! ACCOUNT DIRECT...: EXCELLENT DAY RATES AVAILABLE

Senior Account Executive with progression to Account Manager, Me...: Excellent package

Medical Writer: Bonus Scheme, PTO &Private Healthcare

Principal Health Economist - North-West: Negotiable

Associate Medical Director: Excellent PTO, bonus and 401k package

Medical Writer: Salary TBC

Manager - Immunology, Therapeutic Area Communications & Publ...: Competitive Salary Offered

Account Director: Competitive Salary Offered

Account Director – Healthcare Marketing – Berks: Salary TBC

Editorial Manager - MedComms: DOE

Account Manager / Account Director: Competative

Senior Account Manager: Competitive Salary Offered

Senior Editorial Assistant – Greater Manchester: DOE

Subscribe to our email news alerts

PMHub

Add my company

Novasecta

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

Is China ready for a pharmaceutical gold rush?: Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance: Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis: Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...